Patent intelligence · CA
CA 2883399
REDUCTION AU MINIMUM DE DEPOTS LIPIDIQUES BIOLOGIQUES SUR DES LENTILLES DE CONTACT
REDUCTION AU MINIMUM DE DEPOTS LIPIDIQUES BIOLOGIQUES SUR DES LENTILLES DE CONTACT
Patent details — CA 2883399
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Apr 17, 2014
- Expiration
- Apr 12, 2034
- Applicant
- BAUSCH & LOMB [US]
Quick answer
CA 2883399 (REDUCTION AU MINIMUM DE DEPOTS LIPIDIQUES BIOLOGIQUES SUR DES LENTILLES DE CONTACT) is held by BAUSCH & LOMB [US]. Status: granted. Granted Apr 17, 2014. Expires Apr 12, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAUSCH & LOMB [US]
- Grant date
- Expiration
- Claims
- —
More from BAUSCH & LOMB [US]
Related pharmaceutical patents in our USPTO index.
-
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 2020239601
CROSSLINKED POLYMERIC NETWORK AND USE THEREOF
granted -
US 2019151500
OPHTHALMIC VISCOELASTIC COMPOSITIONS
granted -
CA 3043000
DERIVES DE PROSTAGLANDINE LIBERANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DU GLAUCOME A TENSION NORMALE
granted -
US 2016213609
OPHTHALMIC SUSPENSION COMPOSITION
granted -
US 2015038439
METHOD FOR PREPARING SUSPENSIONS OF LOW-SOLUBILITY MATERIALS
granted -
US 2014206764
Poly(Nitrogen/Amine) Derivatives of a Natural Wax and Ophthalmic Compositions
granted -
US 2014142182
Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
granted
Frequently asked questions
What is US patent 2883399?
CA 2883399 (REDUCTION AU MINIMUM DE DEPOTS LIPIDIQUES BIOLOGIQUES SUR DES LENTILLES DE CONTACT) is held by BAUSCH & LOMB [US]. Status: granted. Granted Apr 17, 2014. Expires Apr 12, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2883399?
BAUSCH & LOMB [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2883399 expire?
Our index shows an expiration date of Apr 12, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.